LOTTE Biologics Secures Contract Development and Manufacturing Agreement 

with a Japan-Based Global Pharmaceutical Company

Seoul, South Korea, April 6, 2026 – LOTTE Biologics (Co-CEOs James Park and Yoo-yeol Shin) announced that it had signed a contract development and manufacturing agreement with a Japan-based global pharmaceutical company.

The company noted that this partnership represents a step toward building a strategic collaboration framework in biologics development and manufacturing.

It is also expected to serve as a meaningful starting point for a deeper collaboration, further accelerating LOTTE Biologics’ competitiveness in the global market, including Japan.